News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INNOPHARMA Appoints John C. Deighan as Chief Financial Officer


5/9/2012 11:53:40 AM

PISCATAWAY, N.J., May 9, 2012 /PRNewswire/ -- InnoPharma, Inc. today announced the appointment of John C. Deighan to the role of chief financial officer, whereby he will be responsible for all aspects of the Company's finance, accounting, planning, treasury and administrative functions. Mr. Deighan has 20 years of experience directing corporate finance functions at life sciences companies.

Commenting on the appointment, Navneet Puri, Ph.D., president & CEO of InnoPharma, stated, "John's specialty pharmaceutical experience and strategic and tactical planning skills will be critical and accretive assets to the InnoPharma team. We look forward to working with John as we continue to build our business and execute on our goals."

Prior to joining InnoPharma, Mr. Deighan was chief financial officer of Eagle Pharmaceuticals, a hospital specialty company focused on reformulating and improving injectable drugs. Mr. Deighan established the financial and administrative functions of Eagle, and participated in the negotiation of licensing and financing deals for the Company, in addition to his involvement in various strategic and operational decisions of the company. Previously, Mr. Deighan held the position of corporate controller at Orchid Cellmark, a DNA testing services laboratory and of divisional controller at Alpharma, a diversified global pharmaceutical company. Mr. Deighan received a Bachelor of Science in business administration from the State University of New York at Oswego, and is a certified public accountant.

About InnoPharma, Inc.:

InnoPharma is a sterile product development company, focused on developing niche generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. InnoPharma has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at www.innopharmainc.com.

SOURCE InnoPharma, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES